Transcriptional Repression of Mad-Max Complex by Human
Umbilical Cord Blood Stem Cells Downregulates
Extracellular Signal-Regulated Kinase in Glioblastoma
posted on 2013-11-22, 00:00authored byKiran Kumar Velpula, Venkata Ramesh Dasari, Andrew J. Tsung, Dzung H. Dinh, Jasti S. Rao
Previously, we have shown that human umbilical cord blood stem cell (hUCBSC) treatment downregulate cyclin
D1 in glioma cells. To study the cell cycle progression and investigate the upstream molecules regulating cyclin
D1 expression, we analyzed the involvement of extracellular signal-regulated kinase (ERK) and its functionality
after treatment with hUCBSC. We observed downregulation of pERK after hUCBSC treatment at both transcriptional
and translational levels. Increased translocation of ERK from cytoplasm to the nucleus was observed
in glioma cells, whereas hUCBSC cocultures with glioma cells showed suppressed nuclear translocation. This
finding suggests that hUCBSC regulates ERK by suppressing its phosphorylation at phospho-Thr202/Tyr204
retarding pERK nuclear translocation. ERK promoter analysis has shown c-Myc binding sites, indicative of
possible transcriptional interactions that regulate cyclin D1 and ERK expression levels. Treatment of U251 and
5310 glioma cells with U0126, a MEK/ERK inhibitor receded pERK and c-Myc levels. In another experiment,
U251 and 5310 cells treated with 10074-G5, c-Myc/Max inhibitor displayed reduction in pERK and c-Myc levels
suggestive of a positive feedback loop between ERK/c-Myc/Max molecules. In the present study, we show that
glioma cells exhibit abundant c-Myc expression and increased c-Myc/Max activity. In contrast, the glioma cells
cocultured with hUCBSC demonstrated high Mad1 expression that competitively binds to Max to repress the c-
Myc/Max mediated gene transcription. Our studies thus elucidate the potential role of hUCBSC in controlling
glioma cell cycle progression and invasion by limiting Max binding to c-Myc, thus regulating the expression of
glioma cell cycle and invasion associated molecules such as ERK, integrins via increased levels of Mad1 expression.
Funding
This project was supported by award
number NS057529 (to J.S.R.) from the National Institute of
Neurological Disorders and Stroke (NINDS).